Abstract
In medical oncology, targeted therapy has emerged over the last decade, as the most promising strategy to fight cancer. In addition, a more complete understanding of tumor heterogeneity and pharmacology of the more conventional anti-cancer agents has led to development of metronomic chemotherapy (MC) (i.e. a more frequent administration of anticancer agents at lower doses then the usual maximally tolerated dose because it has been realized that time of exposure to an effective drug concentration is more important than simply the dose/m2 or kg.), Here, we discuss the nature of the specificity of targeted anti-cancer treatments and conclude that optimizing the schedule is an effective way to improve treatment selectivity.
Keywords: Metronomic, targeted therapy, cancer, MTD, chemotherapy, oncology, specificity of targeted anti-cancer treatments, treatment selectivity
Current Topics in Medicinal Chemistry
Title:Can Targeted Therapy be Successful without Metronomic Scheduling ?
Volume: 12 Issue: 15
Author(s): Nicolas Andre, Eddy Pasquier and Barton Kamen
Affiliation:
Keywords: Metronomic, targeted therapy, cancer, MTD, chemotherapy, oncology, specificity of targeted anti-cancer treatments, treatment selectivity
Abstract: In medical oncology, targeted therapy has emerged over the last decade, as the most promising strategy to fight cancer. In addition, a more complete understanding of tumor heterogeneity and pharmacology of the more conventional anti-cancer agents has led to development of metronomic chemotherapy (MC) (i.e. a more frequent administration of anticancer agents at lower doses then the usual maximally tolerated dose because it has been realized that time of exposure to an effective drug concentration is more important than simply the dose/m2 or kg.), Here, we discuss the nature of the specificity of targeted anti-cancer treatments and conclude that optimizing the schedule is an effective way to improve treatment selectivity.
Export Options
About this article
Cite this article as:
Andre Nicolas, Pasquier Eddy and Kamen Barton, Can Targeted Therapy be Successful without Metronomic Scheduling ?, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531432
DOI https://dx.doi.org/10.2174/156802612803531432 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Apoptotic Signaling Pathways as a Target for the Treatment of Liver Diseases
Mini-Reviews in Medicinal Chemistry Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Traditional Uses, Phytochemistry, Pharmacology and Anticancer Activity of Açaí (Euterpe oleracea Mart): A Narrative Review
Current Traditional Medicine CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology MicroRNA-490-5P Targets CCND1 to Suppress Cellular Proliferation in Glioma Cells and Tissue Through Cell Cycle Arrest
Current Neurovascular Research Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Cell Bystander Effect Induced by Radiofrequency Electromagnetic Fields and Magnetic Nanoparticles
Current Nanoscience